Compare iShares Core MSCI EAFE ETF (IEFA) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core MSCI EAFE ETF vs Sanofi SA — how do they compare? iShares Core MSCI EAFE ETF trades at $97.02, while Sanofi SA trades at $43.72 (market cap $104.83B). The key difference: Sanofi SA pays a 5.5% dividend while iShares Core MSCI EAFE ETF pays none, and iShares Core MSCI EAFE ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| IEFA | SNY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $98.56 | $52.34 |
52-Week Low | $81.70 | $41.33 |
Market Cap | — | $104.83B |
Enterprise Value | — | $121.32B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IEFA trades at $95.57, down 0.71% today amid a bearish technical signal. The ETF focuses on developed international equities excluding the U.S. and Canada, offering a 3.30% dividend yield with a low 0.07% expense ratio. Recent news highlights its role in diversification away from S&P 500 concentration risks. Key support and resistance levels are tightly clustered around $96-$97.
The outlook remains mixed; IEFA provides cost-effective exposure to stable international markets but faces headwinds from currency fluctuations and central bank policy shifts. Its bearish technical trend and neutral oscillators suggest near-term consolidation, while long-term investors may value its dividend income and geographic diversification benefits.
SNY trades at $43.97, down 1.55% today, with a bullish technical signal supported by moving averages. The company reported strong Q1 2026 earnings of $1.10 per share, beating expectations, and maintains robust profitability with a 71.92% gross margin. Recent FDA approval for Sarclisa's subcutaneous formulation and expanded AI research collaboration with Aqemia highlight ongoing innovation. Cash flow from operations remains healthy at $10.75 billion for 2025, though net cash flow is minimal at $49 million.
SNY presents a balanced investment case with solid fundamentals and analyst support (44% buy ratings), but faces risks from EU antitrust probes and patent expiration concerns for key drug Dupixent. Valuation metrics appear reasonable with P/E of 19.81 and P/B of 1.29. The stock's outlook depends on successful drug pipeline execution and navigating regulatory challenges, with current price levels offering stability near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core MSCI EAFE ETF
IEFA tracks the MSCI EAFE Investable Market Index, offering broad exposure to large, mid, and small-cap stocks in developed markets across Europe, Australasia, and the Far East. It serves as a low-cost core holding for international diversification, excluding the U.S. and Canada.
Read more on IEFA →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
